🇬🇧 United Kingdom Country × Condition
healthy Clinical Trials in United Kingdom
Active clinical trials for healthy with research sites in United Kingdom. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇬🇧 United Kingdom
Active Trials in United Kingdom (5)
NCT06685913
Recruiting
The Effect of Ketone Esters on Forearm Glucose Metabolism
Enrollment
14 pts
Country
🇬🇧 United Kingdom
University of Exeter
View Trial → NCT06582290
Recruiting
Investigating the Clinical Utility of the Oxford Virtual Autism Assessment Tool (OVAAT)
Enrollment
60 pts
Country
🇬🇧 United Kingdom
Oxford Health NHS Foundation Trust
View Trial → NCT05698862
Recruiting
Mapping the Impact of Gut Microbiota on Brain and Behavior Through the Lens of GABA
Enrollment
60 pts
Country
🇬🇧 United Kingdom
University of Reading
View Trial → NCT07065643
Recruiting
Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction
Enrollment
75 pts
Country
🇬🇧 United Kingdom
University of Aberdeen
View Trial → NCT05943249
Recruiting
Development of Novel MR Techniques Using Volunteer Participants
Enrollment
1,500 pts
Country
🇬🇧 United Kingdom
University College, London
View Trial → Frequently Asked Questions
How many healthy clinical trials are active in United Kingdom?
There are currently 5 active clinical trials for healthy with sites in United Kingdom, of which 5 are actively recruiting patients.
How can I join a healthy clinical trial in United Kingdom?
To join a healthy clinical trial in United Kingdom, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United Kingdom directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are healthy trials in United Kingdom?
Active healthy trials in United Kingdom span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.